标题
CD40–CD40L in Neurological Disease
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 8, Pages 4115
出版商
MDPI AG
发表日期
2022-04-09
DOI
10.3390/ijms23084115
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
- (2021) Luuk van Hooren et al. Nature Communications
- Ras isoforms: signaling specificities in CD40 pathway
- (2020) Arathi Nair et al. Cell Communication and Signaling
- Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma
- (2020) Robert A. Figlin et al. CLINICAL CANCER RESEARCH
- CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
- (2020) Taha Elmetwali et al. Scientific Reports
- LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
- (2020) Anne Berberich et al. Frontiers in Oncology
- Monoclonal Antibody-Based Therapies for Myasthenia Gravis
- (2020) Sawsan Alabbad et al. BIODRUGS
- Safety, Pharmacokinetics and Pharmacodynamics of BI 655064 in Phase 1 Clinical Trials in Healthy Chinese and Japanese Subjects
- (2020) Yasuhiro Tsuda et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
- (2020) Catalina Lee-Chang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Atlas of Inflammation Resolution (AIR)
- (2020) Charles N. Serhan et al. MOLECULAR ASPECTS OF MEDICINE
- Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
- (2020) Jean-Pascal Machiels et al. Journal for ImmunoTherapy of Cancer
- The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis
- (2020) Pedro M. Rodríguez Cruz et al. Frontiers in Molecular Neuroscience
- First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- (2019) Sandra M. M. Irenaeus et al. INTERNATIONAL JOURNAL OF CANCER
- Non-surviving patients with severe traumatic brain injury have maintained high serum sCD40L levels
- (2019) Leonardo Lorente et al. World Neurosurgery
- Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker parameters in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
- (2019) Sudha Visvanathan et al. ANNALS OF THE RHEUMATIC DISEASES
- A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
- (2019) Jodi L. Karnell et al. Science Translational Medicine
- The expression of CD40 correlates negatively with overall- and progression free survival of low- and high-grade gliomas
- (2019) Jan-Michael Werner et al. World Neurosurgery
- Neuroinflammation — a common thread in neurological disorders
- (2019) Nils Erik Gilhus et al. Nature Reviews Neurology
- Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open‐label, noninferiority study
- (2019) Robert C. Harland et al. AMERICAN JOURNAL OF TRANSPLANTATION
- A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti‐ CD 40 monoclonal antibody, in kidney transplantation
- (2019) Flavio Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- CD40 forward signalling is a physiological regulator of early sensory axon growth
- (2019) Laura Howard et al. DEVELOPMENT
- A Novel Anti-Cd40 Monoclonal Antibody, Iscalimab, for Control of Graves’ Hyperthyroidism – A Proof-Of-Concept Trial
- (2019) G J Kahaly et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Concepts for agonistic targeting of CD40 in immuno-oncology
- (2019) David M. Richards et al. Human Vaccines & Immunotherapeutics
- First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody
- (2019) Pascal Espié et al. AMERICAN JOURNAL OF TRANSPLANTATION
- CD40-mediated HIF-1α expression underlying microangiopathy in diabetic nerve pathology
- (2018) Hung-Wei Kan et al. Disease Models & Mechanisms
- Signaling via toll-like receptor 4 and CD40 in B cells plays a regulatory role in the pathogenesis of multiple sclerosis through interleukin-10 production
- (2018) Yoichiro Okada et al. JOURNAL OF AUTOIMMUNITY
- The role of inflammation in the development of epilepsy
- (2018) Amna Rana et al. Journal of Neuroinflammation
- A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
- (2018) Jhanelle E. Gray et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
- (2018) Jodi L. Karnell et al. ADVANCED DRUG DELIVERY REVIEWS
- Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
- (2017) Fredrik N. Albach et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder
- (2017) Hiroki Masuda et al. JOURNAL OF NEUROIMMUNOLOGY
- Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
- (2017) A. Schiza et al. Journal of Translational Medicine
- The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
- (2017) Suzanne A. B. M. Aarts et al. Frontiers in Immunology
- Calcitonin gene-related peptide contributes to peripheral nerve injury-induced mechanical hypersensitivity through CCL5 and p38 pathways
- (2016) Jennifer T. Malon et al. JOURNAL OF NEUROIMMUNOLOGY
- A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
- (2015) A. K. Nowak et al. ANNALS OF ONCOLOGY
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models
- (2015) Masashi Chonan et al. NEURO-ONCOLOGY
- Involvement of CD8+ T Cells in Multiple Sclerosis
- (2015) Marion Salou et al. Frontiers in Immunology
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
- (2015) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- The Signaling Role of CD40 Ligand in Platelet Biology and in Platelet Component Transfusion
- (2014) Chaker Aloui et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Macrophagic and microglial responses after focal traumatic brain injury in the female rat
- (2014) L Turtzo et al. Journal of Neuroinflammation
- Evidence for involvement of the CD40/CD40L system in post-stroke epilepsy
- (2014) Bikui Zhang et al. NEUROSCIENCE LETTERS
- Serum soluble CD40 Ligand levels are associated with severity and mortality of brain trauma injury patients
- (2014) Leonardo Lorente et al. THROMBOSIS RESEARCH
- CD154 Is Released from T-cells by a Disintegrin and Metalloproteinase Domain-containing Protein 10 (ADAM10) and ADAM17 in a CD40 Protein-dependent Manner
- (2013) Daniel Yacoub et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mechanisms underlying sCD40 production in hemodialysis patients
- (2012) Pasquale Esposito et al. CELLULAR IMMUNOLOGY
- Impact of the CD40-CD40L Dyad in Alzheimers Disease
- (2012) Brian Giunta et al. CNS & Neurological Disorders-Drug Targets
- Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain
- (2012) Jennifer T. Malon et al. Neuron Glia Biology
- Immunotherapy Network Launches First Trial
- (2012) Cancer Discovery
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma
- (2010) Fang Xie et al. JOURNAL OF NEUROIMMUNOLOGY
- Traumatic Brain Injury: A Disease Process, Not an Event
- (2010) Brent E. Masel et al. JOURNAL OF NEUROTRAUMA
- From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis
- (2010) John M Lincecum et al. NATURE GENETICS
- Targeting the Ischemic Penumbra
- (2010) P. Ramos-Cabrer et al. STROKE
- Critical role of microglial CD40 in the maintenance of mechanical hypersensitivity in a murine model of neuropathic pain
- (2009) Ling Cao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Interferon-β therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism
- (2009) David Azoulay et al. JOURNAL OF NEUROIMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started